Sherbrooke Park Advisers LLC Exelixis, Inc. Transaction History
Sherbrooke Park Advisers LLC
- $230 Billion
- Q2 2025
A detailed history of Sherbrooke Park Advisers LLC transactions in Exelixis, Inc. stock. As of the latest transaction made, Sherbrooke Park Advisers LLC holds 24,843 shares of EXEL stock, worth $960,678. This represents 0.48% of its overall portfolio holdings.
Number of Shares
24,843
Previous 14,194
75.02%
Holding current value
$960,678
Previous $524 Million
108.94%
% of portfolio
0.48%
Previous 0.24%
Shares
9 transactions
Others Institutions Holding EXEL
# of Institutions
697Shares Held
259MCall Options Held
1.41MPut Options Held
1.55M-
Black Rock Inc. New York, NY33.5MShares$1.3 Billion0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA27.5MShares$1.06 Billion0.02% of portfolio
-
Farallon Capital Management LLC San Francisco, CA16MShares$620 Million3.18% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny15.8MShares$612 Million0.99% of portfolio
-
State Street Corp Boston, MA11.4MShares$440 Million0.02% of portfolio
About EXELIXIS, INC.
- Ticker EXEL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 321,832,000
- Market Cap $12.4B
- Description
- Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...